AlphaYou
Overview
Key stats
Fundamentals Sep 12- Open
- $268.03
- 52-wk high
- $281.07
- High
- $270.40
- 52-wk low
- $169.49
- Low
- $265.25
- Prev close
- $266.35
- Mkt cap
- $641.88B
- P/E
- 31.0x
- Volume
- 4.71M
- Fwd P/E
- 20.8x
- Beta
- 0.23
- Div yield
- 1.96%
- P/S
- 6.5x
- P/B
- 7.6x
- Profit margin
- +21.5%
- Op margin
- +29.2%
- ROE
- +25.7%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsSmart money
8 funds hold a position, insiders have been net selling, and 1 fin-fluencer is discussing it.
What funds are doing
Earnings
Earnings came in 2.1% above what analysts expected.
Earnings per share
$2.84 expected
Revenue
No comparable estimate
FY2026 guidance
$100.80B to $101.40B
No comparable estimate
Reports Oct 13, 2026, in 30 days
EPS expected
$2.31 to $2.49
Revenue expected
4 analysts
Last 30 days
Analysts cutting estimates
What the company said
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $23.99B | $24.56B | $24.06B | $25.31B |
| Cost of what it sold | $7.30B | $7.97B | $6.86B | $6.81B |
| Gross profit | $16.69B | $16.60B | $17.20B | $18.50B |
| What it spent | ||||
| Research and development | $3.67B | $4.25B | $3.53B | $3.65B |
| Sales and admin | $5.92B | $6.95B | $6.03B | $6.43B |
| Other operating costs | — | -$200.0M | $1.25B | $1.25B |
| Total operating expenses | $9.59B | $11.01B | $10.81B | $11.33B |
| What was left | ||||
| Operating profit | $7.10B | $5.59B | $6.39B | $7.17B |
| Interest on debt | $245.0M | $214.0M | $272.0M | $281.0M |
| Profit before tax | $7.49B | $4.97B | $5.99B | $6.75B |
| Tax | $2.34B | -$150.0M | $755.0M | $1.21B |
| Net profit | $5.15B | $5.12B | $5.24B | $5.53B |
| EBITDA | $9.29B | $7.19B | $8.27B | $8.99B |
Technicals
Price structure
This stock is in a strong uptrend.
Trend
Strong uptrend
80 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage leans bullish
Tone of tracked coverage
AbbVie's Immunology Franchise: From Skyrizi & Rinvoq to What's Next
NeutralSep 10Energy Transfer LP to transfer stock exchange listings to Texas Stock Exchange
NeutralSep 10Johnson & Johnson gets CE mark for Acuvue Oasys MAX 2-Week lens
BullishSep 10Innovation can’t wait: getting new medicines to patients faster
NeutralSep 10Alumis at Cantor conference: psoriasis strength, lupus setback
NeutralSep 10Johnson & Johnson (JNJ) Stock Could Be A Bargain On Cash Flow, Fully Priced On Earnings
NeutralSep 10Mid-America Apartment Communities (MAA), What Is Behind Its Latest Update?
Leans bullishSep 9Get Smart About Atrial Fibrillation
NeutralSep 9
Macro
20 macro signals shaping JNJ right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results